Abstract Scopolamine, a muscarinic antagonist, impairs memory performance in both humans and animals. In this study, repeated measurements of regional cerebral blood flow (rCBF) were made in normal volunteers whilst performing auditory verbal memory tasks, before and after the administration of scopolamine (0.4 mg s.c.) or placebo. Compared to placebo, scopolamine increased blood flow in the lateral occipital cortex bilaterally and the left orbitofrontal region. Scopolamine decreased rCBF in the region of the right thalamus, the precuneus and the right and left lateral premotor areas. Scopolamine attenuated memory-task-induced increases of rCBF in the left and right prefrontal cortex and the right anterior cingulate region. These data suggest that acute blockade of cholinergic neurotransmission affects diverse brain areas, including components of the visual and motor systems, and, in addition, modulates memory task activations at distinct points in a distributed network for memory function.
Introduction
Scopolamine (hyoscine hydrobromide) is a muscarinic antagonist with central and peripheral actions (Ketchum et al. 1973; Heller-Brown 1990) . It has been extensively investigated for its effects on higher cognitive processes particularly memory and attention (see Collerton 1987; Kopelman 1987 for reviews). In summary, scopolamine impairs performance on memory tasks that exceed the limited capacity of primary memory (Kopelman 1987) . Thus while digit, word and block span is unaffected, scopolamine impairs the performance on supraspan tasks such as the recall of series of nine digits (Drachman and Leavitt 1974) or the free recall of a supraspan word list (Crow and Grove-White 1973) . In keeping with effects on secondary memory, scopolamine impairs performance at the beginning and in the mid-portion of the serial position curve but the recency effect is unimpaired (Crow and Grove-White 1973) . Despite these findings, it remains a matter of continuing debate whether attentional and or memory mechanisms are primarily impaired by scopolamine (Kopelman 1987; Sahakian 1988) .
A clearer understanding of scopolamine's effect in the CNS might be obtained by determining which brain areas are targeted, functionally, by scopolamine administration in humans. Positron emission tomography (PET) can be used to measure drug-induced changes in regional cerebral blood flow (rCBF) or glucose utilization which, under most circumstances, are valid indices of neuronal activity in vivo (McCulloch 1982; Soncrant et al. 1986; Raichle 1987; Posner et al. 1988) . In addition, when a pharmacological manipulation is combined with a psychological challenge, sites of functional interaction between a drug and the rCBF change induced by a psychological task can be determined Grasby et al. 1992) . Using PET, we report the effects on rCBF of a single subcutaneous dose of scopolamine (0.4 mg) in normal volunteers whilst subjects performed subspan and supraspan auditory-verbal memory tasks. A supraspan-subspan memory activation paradigm was chosen, as scopolamine impairs supraspan word list re-call (see above) and because the pattern of rCBF activations with this paradigm has been characterized previously . Specifically, our aims were to determine (1) the brain areas altered by scopolamine administration, as indexed by changes in rCBF, and (2) the brain sites of interaction between scopolamine and the rCBF activations induced by a supraspan memory task.
Materials and methods

Subjects
Twelve right-handed male volunteers (age range 21-36 years) took part in the study, which was approved by the local hospital ethics committee and the Advisory Committee on the Administration of Radioactive Substances (ARSAC), UK.
Drug administration
Each subject underwent six PET measurements of rCBF over a 90 min period. Two measurements of rCBF were undertaken before (t=-12 and -2 min), and four measurements after subcutaneous scopolamine (0.4 mg) or placebo (0.5 ml saline for injection) (t=-+15, +25, +55, +65 min for scopolamine; t=+20, +30, + 50, +60 min for placebo). Scan times post scopolamine were chosen on the basis of scopolamine kinetics and the time course of impairment of memory function. Scopolamine is rapidly absorbed following subcutaneous injection and impairment of memory function is usually seen within 30 to 60 rain. The 5-min difference in post-drug scan times between the placebo and scopolamine conditions was because the placebo group was used as a data base for comparison with other drug-memory interaction studies with slightly different scanning times (see Grasby et al. 1992) . Subjects were blind to the drug administered. Six subjects received scopolamine and six received placebo.
Experimental design
The design of this experiment is illustrated in Fig. 1 . Subjects performed memory tasks during PET scanning. The tasks used were a subspan memory task (M-) performed during the first, third and fifth scans and a supraspan task (M+) during the second, fourth and sixth scans. In the subspan task, subjects were asked to remember and immediately verbally recall a series of five-word lists presented auditorily. Nine different five-word lists were presented over the 2 min of the PET scan. In the supraspan task, subjects were required to remember and immediately verbally recall a 15-word list presented auditorily. The 15-word list was presented three times during the PET scan, thus the number of words heard in both tasks was 45 in total (5x9, 15x3). The essential difference between the subspan and supraspan tasks was taken to be the greater engagement of long-term memory processes in the supraspan condition (see Grasby et al. 1993) . Words were presented at the rate of one every 2 s. Different 15-word lists were used for each PET scan. Words were high frequency, concrete, imageable and were taken from the Oxford Psycholinguistic Data Base (Quinlan 1992) . Scopolamine or placebo was given after the second scan. The subjects eyes were closed throughout scanning. The total number of words correctly recalled from each subspan and supraspan task was noted.
PET scanning
Scans were obtained using a CTI model 931-08/12 PET scanner (CTI, Knoxville, Tenn., USA) (Spinks et al. 1988 ). Scans were reconstructed using a Hanning filter with a cut-off frequency of 0.5 giving a transaxial resolution of 8.5 mm full width at half maximum (FWHM) and an axial resolution of 6.75 mm for each of 15 transverse planes, with a resulting total field of view of 10.13 cm in this direction. To index rCBF, subjects inhaled trace amounts of 15C02, mixed with air, at a concentration of 6 MBq/ml and a flow rate of 500 ml/min through a disposable oxygen face mask for a period of 2 min. Two PET scans were collected over a period of 2.5 rain beginning 0.5 min before the inhalation of lsC02 (background scan duration 0.5 min, second scan duration 2 min) (adapted from Lammertsma et al. 1990) . In this study, the integrated counts per pixel for the 2-rain build-up phase of radioactivity in the brain during 15C02 inhalation were used as an index of rCBF (Mazziota et al. 1985; Fox and Mintun 1989) .
Measurement of side effects of scopolamine administration
Subjective stress and arousal were assessed on three occasions (t=-15 min pre-scopolamine/placebo and t=+30 min, +60 rain post-scopolamine/placebo) using a 24-item questionnaire (Mackay et al. 1978) . In addition, subjects rated the symptom of dry mouth on a visual analogue scale (0="not at all", 100="a great deal").
Data analysis
Each reconstructed rCBF scan consisting of 15 primary transverse planes was interpolated to 43 planes to render the voxels approximately cubic. For each subject, head movement between scans was corrected by aligning all scans using automated image registration (AIR) software specfically developed for this purpose (Woods et al. 1992) . Images were then transformed into a standard stereotactic space (Friston et al. 1989 (Friston et al. , 1991a . Such transformation of the data allows for pixel by pixel averaging of data across subjects. In the standard space, one voxel represents 2x2x4 mm in the x, y and z dimensions, respectively, allowing direct cross-reference to the anatomical features in a standard stereotactic atlas (Talairach and Tournoux 1988) . A gaussian filter (20 mm FWHM) was applied to smooth each image to account for inter-subject differences in gyral and functional anatomy and to suppress high-frequency noise in the images.
Differences in global activity within and between subjects were removed by analysis of covariance (Wildt and Ahtola 1978) on a pixel by pixel basis with global counts as covariate and regional activity across subjects for each task as treatment. This procedure was undertaken as inter-and intra-subject differences in global CBF reduce the likelihood of detecting alterations in rCBF following physiological stimulation (Friston et al. 1990 ). It should be noted that scopolamine and memory-induced changes in rCBF represent relative increases or decreases of rCBF following the normalization of global radioactive counts to a flow value of 50 ml/dl/min.
For each pixel, in stereotactic space, the analysis of covariance (ANCOVA) generated six condition-specific (i.e., scans 1-6), mean rCBF equivalent values (normalized to 50 ml/dl/min) and an associated error variance. This error variance was computed independently for the placebo and scopolamine groups using a completely randomized block design ANCOVA. The ANCOVA procedure assumes that the magnitude of rCBF change following task activation is additive rather than proportional to global flow. The experimental validity of the additive model has been shown by Friston et al. (1990) and Ramsay et al. (1993) . Another assumption is that of no systematic change in the global covariate (global radioactivity counts) across conditions. This assumption was tested and confirmed by analysis of variance (ANOVA) on the global radioactivity counts (F=l.04, df5, 30, P>0.05).
Statistical comparisons
The changes of interest were: 1. The main effect of scopolamine compared to placebo (rCBF changes due to scopolamine compared to placebo under both subspan and supraspan conditions). 2. The main effect of the memory task (rCBF increases due to the supraspan task compared to the subspan memory task). This effect was determined using the group of subjects given placebo. 3. The interaction effect of scopolamine on the memory task, that is scopolamine-induced rCBF attenuations or augmentations of supraspan task rCBF increases. This represents the interaction: memory-induced rCBF activations (supraspan -subspan), pre-scopolamine versus post-scopolamine. To control for any non-specific attenuations or augmentations of supraspan rCBF activations, due to time or placebo effects, the placebo group was similarly examined. Qualitative comparisons between the attenuations and augmentations in the two groups were then made. To do this the same subset of pixels (identified on the basis of supraspan rCBF increases in the scopolamine group) was examined in the placebo group to identify possible time/placebo interaction effects.
The above effects were computed on a pixel by pixel basis using the t statistic with the appropriate linear contrasts (Hand and Taylor 1991) and adjusted error variance. The resulting sets of t values constitute statistical parametric maps [SPM(t)] (Friston et al. 1991b ). With so many comparisons being made, many t values reach conventional levels of significance by chance. Therefore a strict threshold of P<0.001 per pixel was used to define the profile of scopolamine-induced rCBF changes compared to placebo. This threshold has been found to protect against false positives (Bailey et al. 1991 ). For the memory task comparison the same threshold was also used.
Pixels significantly activated in the supraspan-subspan comparison in the scopolamine group at P<0.001 were further analyzed when computing the attenuating and augmenting effect of scopolamine or placebo in these pixels. The threshold for the attenuating or augmenting effects of scopolamine or placebo on memory activation was set at P<0.05. Thus, the final probability of a main effect of memory activation and a drug-induced attenuation (augmentation) of memory activation, occurring in the same pixel, is the product of the probabilities P<0.001 xP<0.05 (P<0.00005).
Image analysis was performed using SPM software (MRC Cyclotron Unit, London, UK) on a SPARC 1 workstation (Sun Microsystems, Surrey, UK) using an interactive image analysis software package ANALYZE (Biodynamic Research Unit, Mayo Clinic, USA ; Robb 1990 ). Calculations and image matrix manipulations were performed in PRO MATLAB (Mathworks, New York, USA).
Results
Memory performance
Scopolamine had no effect on the number of words correctly recalled in the five-word list task; a high level of performance was recorded throughout the study (97% or above correct recall for all scans). A two-way ANOVA, drug (2) xsupraspan task (3) showed a significant effect of drug on supraspan task (F=3.568, df2, P<0.05; Table   1 ). Scopolamine reduced the numbers of words correctly recalled in the 15-word list task compared to placebo, an effect most apparent in the second post-drug supraspan trial, in which recall on the first, second and third presentation of a 15-word list was impaired.
Sites of scopolamine-induced increases of rCBF compared to placebo Three foci of increased rCBF were observed. Two foci were located in the left and right lateral occipital cortex and one in the left inferior frontal region (Table 2, Fig. 2 ).
Sites of scopolamine-induced decreases of rCBF compared to placebo Decreases of rCBF were noted in the region of the right thalamus, the precuneus and the right and left premotor areas (Table 2, Fig. 3 ).
Sites of memory (supraspan)-induced increases of rCBF in the placebo-treated group Memory (supraspan-subspan) induced increases of rCBF were noted in the left and right prefrontal cortex, the pre- Scopolamine attenuated supraspan-induced rCBF increases at four locations. These attenuations were localized to the left prefrontal cortex (predominantly the middle frontal gyms), the right prefrontal cortex (middle and superior frontal gyri), a region bordering the right anterior cingulate and adjacent right prefrontal cortex (predominantly middle frontal gyrus), and the left inferior lateral parietal region (predominantly BA 39/40) ( Table  3 , Figs. 5, 7). Comparison of the attenuation loci showed that of the four locations identified above, the placebo condition only attenuated supraspan activations in the left inferior parietal region (Fig. 5) . Placebo was also associated with attenuation of supraspan rCBF increases in the superior aspect of the left prefrontal region, but this area was not congruent with the attenuations seen in the scopolamine group (see Fig. 5 ).
Sites of scopolamine-and/or placebo-induced augmentation of supraspan increases of rCBF Scopolamine augmented supraspan-induced rCBF increases in the region of the right precuneus (Table 3 , A similar focus of augmentation was seen in the placebo condition in the region of the precuneus. Placebo augmentations (in some cases extending over a few transverse planes only), were also noted in the right prefrontal cortex, right anterior cingulate region and the right and left lateral parietal regions (Fig. 6 ).
Stress, arousal and side effects of s c o p o l a m i n e administration Subject-rated levels of stress and arousal decreased during the time course of the PET study in both the scopolamine-and placebo-treated groups -stress: placebo 19+2 to 14_+2, scopolamine 22_+10 to 17_+9; arousal: placebo -1_+2 to -7_+3, scopolamine 4_+4 to -6_+4 (mean_+SD). On the visual analogue scale, all the subjects treated with s c o p o l a m i n e reported an increase in rating of dry mouth ( p r e -s c o p o l a m i n e m e d i a n score=15, p o s t -s c o p o l a m i n e m e d i a n score=70). 
Discussion
In this study, scopolamine administration had regionally selective effects on an index of relative rCBE Scopolamine increased rCBF in the lateral occipital cortex and the left orbitofrontal region and decreased rCBF in the region of the right thalamus, the precuneus and the right and left premotor areas. In addition, however, this study showed that scopolamine acted also in other areas of the brain, specifically modulating rCBF activations due to a supraspan memory task. The sites of scopolamine-induced changes of rCBF in this study show some similarities with the changes in regional cerebral glucose consumption following scopolamine administration (0.25 mg/m 2 i.v.) in normal volunteers (Blin et al. 1994 ). In the study by Blin and colleagues, increases of absolute glucose consumption were noted in nearly all brain regions studied using a region of interest analysis, with a global increase of glucose consumption of 14%. The greatest increases in glucose consumption (20-21%) were in the occipital, parietal association and hippocampal regions, whilst the thalamus showed the smallest change (increase 5%). In our study, using an index of rCBF that was normalized to global flow, relative increases of rCBF were also located in the occipital region and relative decreases were noted in the thalamus. However, we did not detect relative increases of rCBF in hippocampal and parietal association cortex regions. Such discrepancies are not altogether surprising given the different doses, routes and time of drug administration, and possibly imaging methods and data analysis techniques. We are aware of one other study reporting rCBF changes following scopolamine administration in normal volunteers. Honer et al. (1988) measured rCBF using the xenon inhalation technique. Following scopolamine 7.3 gg/kg i.v., global reductions in CBF were noted after 25 rain, the greatest reductions being in the frontal regions. The highest per cent reduction in rCBF (-22%) was reported over the superior posterior frontal areas. This area is in a similar location to the reductions of rCBF (normalized to global flow), localized to the premotor regions, in our study. The smallest reductions of rCBF in Honer's study were reported for the occipital cortex (-11%), where we detected the greatest increase in relative rCBF, normalized to global flow. Thus this study, using a different imaging method, shows a degree of correspondence with our results. Furthermore, our re-sults mirror the opposite effects seen with the anticholinesterase inhibitor physostigmine. In rats, physostigmine increases glucose metabolism in the anterior thalamus and decreases metabolism in the occipital and parietal cortex (Ray et al. 1992; Blin et al. 1994) . A trend for increased thalamic metabolism has also been reported following physostigmine administration in Alzheimer's patients (Blin et al. 1994) . Taken together, these results would suggest that functional activity (indexed by rCBF or glucose metabolism) in the occipital cortex and thalamus are particularly sensitive to the effects of manipulations of cholinergic neurotransmission in man.
Pharmacological mechanism of scopolamine-induced changes in rCBF
Either of two mechanisms might account for the observed effects of scopolamine on rCBF; a direct effect of scopolamine on cerebral blood vessels or an effect of scopolamine on neuronal firing, with consequent changes in glucose metabolism and rCBF. Evidence for a direct effect on cerebral vessels would be the fact that the cerebral vasculature contains cholinergic fibres and muscarinic receptors and that acetylcholine is vaso-active (Burnstock 1980; Edvinsson et al. 1993) . If a direct effect of scopolamine on the cerebral vasculature had occurred in this experiment, a change of global CBF might have been expected. Although we did not measure absolute rCBF in this study (arterial cannulation was not performed), we did not detect any changes in the global radioactivity counts for subjects across scans (P<0.05, ANOVA, F=l.04, df 5, 30). More convincingly, highly Talairach and Tournoux atlas regionally selective effects of scopolamine on rCBF were observed and included both increases and decreases of rCBF and modulation of neurogenic (psychological task) induced rCBF changes. It would appear unlikely that such changes were the direct effect of regionally selective vasodilation and vasoconstriction of cerebral blood vessels.
Scopolamine's antagonist action at muscarinic receptors results in the blockade of presynaptic and postsynaptic muscarinic receptors (Bymaster et al. 1993 ). Acting at the presynaptic autoreceptor on the cholinergic neuron, scopolamine enhances acetylcholine release; however, overall muscarinic cholinergic neurotransmission is likely to be blocked due to antagonism at the postsynaptic muscarinic receptor. The rCBF changes noted in this study may therefore reflect the overall functional effects of blockade of cholinergic (muscarinic) neurotransmission. However, this may be a oversimplification because (1) increased presynaptic release of acetylcholine may result in enhanced nicotinic neurotransmission, (2) muscarinic antagonists may increase dopamine release (Dewey et al. 1993) , (3) drug effects in vivo may reflect actions on integrated neuronal circuits involving multiple neurotransmitters (see McCulloch 1982) .
Functional considerations of cholinergic modulation of occipital, thalamic and premotor rCBF
The spatially restricted focus of rCBF activation in the lateral occipital cortex was unexpected. The use of smoothing filters at the stage of data analysis means that the reported rCBF values in the pixel of maximum rCBF change represent blood flow in a weighted spherical domain of about 20 mm diameter. Given the bilateral nature of the activations, this would suggest that the area of maximal rCBF change is located in the lateral rather than medial aspect of the occipital cortex. Furthermore, visual stimulation experiments using the imaging methods and data analysis described above allow a clear separation of medial and lateral occipital activations (Watson et al. 1993) . These foci of activation are in the region of the recently described human visual motion area V5 of the lateral occipital cortex, although the mean spatial co-ordinates for V5 are slightly more lateral to the foci of maximal change induced by scopolamine [left: V5 -44, -70, 0 vs -32, -78, 0; right: V5 +40, -68, 0 vs +20, -80, 12; co-ordinates in x, y and z planes, respectively (Watson et al. 1993) ]. The occipital changes might relate to the reported transient impairment of ocular accommodation, including blurred vision and mydriasis, that occurs with scopolamine. However, the subjects' eyes were closed throughout scanning, making this explanation unlikely. Given the anatomical specificity of the rCBF changes in the occipital cortex, we would predict that scopolamine may have distinct effects on aspects of visual processing. In this regard, it is interesting that scopolamine prolongs the latency of the P2 and N3 components of flash-induced visual evoked responses (Bajalan et al. 1986 ); also, anticholinergics induce a state of dreamless sleep (Heller-Brown 1990) and, in high doses, cause visual hallucinations (Crowell and Ketchum 1967; Ketchum et al. 1973) . In addition, during REM sleep, when cholinergic neurotransmission is assumed to be operative (Steriade and McCarley 1990) , glucose metabolism is increased in the lateral occipital areas (Maquet et al. 1990) .
The thalamus has a key role in the control and regulation of cortical activity in both primates and man, with thalamocortical oscillations being postulated to determine states of sleep and arousal (Steriade et al. 1993) . Brain stem cholinergic systems are important for the control of neuronal excitability during the sleep/wake cycle, and brain stem cholinergic neurones directly excite thalamocortical neurones (Steriade and McCarley 1990) . Modulation of thalamic function might therefore have caused the observed changes of cortical activity in this study, although more widespread alterations might have been expected as bilateral thalamic infarction results in widespread reductions in cortical glucose metabolism (Baron et al. 1986 ). Blood flow in the lateral premotor area was reduced by scopolamine administration. The lateral premotor areas are implicated in movement control, particularly the planning and selection of movement (Passingham 1993) . Anticholinergics, such as scopolamine, have mild antiparkinsonian effects and can be used in the treatment of tremor and dystonia (Lang 1989; Cedarbaum and Schleifer 1990) . Although anticholinergics may act in Parkinson's disease and other movement disorders at the level of the basal ganglia (Calne 1978; Leigh 1989; Kernel et al. 1992 ), the results presented here would suggest that the lateral premotor areas might be considered a site at which some of the clinical effects of anticholinergics on motor symptoms might be mediated.
Scopolamine-induced modulation of supraspan increases of rCBF
The main effect of scopolamine on rCBF, as described above, was to change rCBF in select brain areas such as the lateral occipital cortex, thalamus and premotor areas. These main effects occurred under both the subspan and supraspan conditions. Whilst any of these sites might be a potential candidate region for the amnesic effect of scopolamine, the most direct evidence for the location of scopolamine's amensic effect was obtained by the anatomical distribution of scopolamine/memory interactions.
The increases of rCBF in the supraspan condition in the placebo scans were as reported previously and illustrate that a network of anatomically distant areas are associated with supraspan memory activation . A similar set of regions was activated in the scopolamine group by the supraspan task (compare Figs. 4 and 5) . We chose the scopolamine supraspan activations, defined by a subset of pixels in stereotactic space, to examine the pattern of modulatory effects of scopolamine on memory-related rCBF increases. Within the network of regions so identified, scopolamine was found to have modulatory (attenuating) effects in the left and right prefrontal cortex, the right anterior cingulate region and the left inferior lateral parietal area and augmenting effects in the precuneus (Figs. 5, 6 ). When these same areas were examined in the placebo condition, only the left inferior lateral parietal and precuneus showed similar modulations (Table 3, Figs. 5, 6 ). Thus, scopolamine appears to selectively modulate left and right prefrontal/right anterior cingulate memory activations (Fig. 7) . These attenuating effects were also noted when making a quantitative comparison between the scopolamine and placebo groups (data not shown), although the attenuation focus in the left prefrontal cortex reached significance in a few pixels only. These attenuating effects may represent the direct neural correlate of scopolamine's amnesic effect.
The exact role of prefrontal areas in mnemonic function remains a matter of continuing debate; thus, while many aspects of mnemonic function remain intact in patients with prefrontal lesions, other subtle aspects of memory function, such as judgements of item recency, temporal order and the use of mnemonic strategies, may be impaired (see Shimamura et at. 1991) . Recent memory activation studies using PET suggest that the left and right prefrontal cortex have distinct roles in episodic memory function with the left prefrontal cortex being involved in the processes of encoding and or the organization of material to be remembered, while the right prefrontal cortex may be involved in the retrieval and or verification of episodic memories (Shallice et al. 1994; Tulving et at. 1994) . The data in this paper would suggest that scopolamine's amensic effect might be mediated via an action on those memory processes subserved by the left and right prefrontal cortices.
A further possible site of scopolamine's amnesic effects is the right anterior cingulate as attenuations of supraspan rCBF increases occurred in this region (Fig. 5) . The right anterior cingulate has been most clearly implicated in attentional tasks (Pardo et al. 1990; Bench et al. 1993) . Scopolamine is reported to impair performance on attentional type tasks such as simple and choice reaction time, digit checking, vigilance and sustained rapid visual information processing (see Rusted 1994) .The attenuation of rCBF responses in this region would therefore suggest that one effect of scopolamine on memory function is in part mediated through an action on attentional mechanisms that involve the anterior cingulate cortex.
We did not detect a cholinergic or memory task modulation of hippocampal rCBF in this experiment. This is surprising given the strong cholinergic projections from the basal forebrain to this structure (McGeer et al. 1987) and the postulated role of the hippocampus in memory function (Squire and Zola-Morgan 1991) . However, there is an often documented mismatch between the regional receptor/terminal innervation density of neuronal systems sensitive to a drug and drug effects on rCBF (see McCulloch 1982) . Furthermore, the theoretical "sparseness" of hippocampal neuronal activation during memory encoding (Rolls and Treves 1990) may explain the failure to detect hippocampal rCBF change during the memory task. Alternatively, or additionally, the memory tasks chosen (subspan and supraspan) may not be sufficiently sensitive to produce a differential activation of the hippocampus in the supraspan task.
Altogether, scopolamine attenuated memory activations in a small number of functionally distinct brain areas. It appears, therefore, that cholinergic neurotransmission modulates a memory network at more than one point. As each point of this memory network is unlikely to be equipotential, in terms of the memory processes subserved (Shallice et al. 1994) , it is possible that scopolamine acts to influence a number of discrete functions, including organizational, verification and attentional mechanisms, that are operative together during memory processing.
